中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 5
May  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(5): 1210-1216

Bidirectional role of triggering receptor expressed on myeloid cells 2-mediated macrophages in liver diseases

DOI: 10.12449/JCH260531

  • Department of Gastroenterology，The Second Affiliated Hospital of Kunming Medical University，Kunming 650000，China

Research funding:

National Natural Science Foundation of China (82360108);

Chen Jie Expert Workstation in Yunnan Province (202305AF150065);

Leading Medical Talents in Yunnan Province (L-2019013);

Kunming Medical University Master’s Research Innovation Fund (2025S098)

More Information
  • Corresponding author: TANG Yingmei， tangyingmei_med@kmmu.edu.cn （ORCID： 0000-0002-0731-4198）
  • Received Date: 2025-07-31
  • Accepted Date: 2025-10-20
  • Published Date: 2026-05-25
    Abstract
  • As a key receptor for immune regulation， triggering receptor expressed on myeloid cells 2 （TREM2） plays an important role in the development and progression of liver diseases， but its specific mechanisms and regulatory strategies in different types and stages of liver diseases remain to be systematically elucidated. This article systematically reviews the molecular characteristics and signaling pathways of TREM2， elaborates on the multiple functions of TREM2+ macrophages in lipid metabolism， phagocytic function， inflammatory response， and fibrosis， and analyzes the dynamic and bidirectional roles of TREM2 in different liver diseases. Targeting the TREM2 signaling axis is expected to become a new strategy for regulating the hepatic immune microenvironment and intervening in disease progression.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    COLONNA M. The biology of TREM receptors[J]. Nat Rev Immunol, 2023, 23( 9): 580- 594. DOI: 10.1038/s41577-023-00837-1.
    [2]
    ZHANG LS, XIANG XY, LI YH, et al. TREM2 and sTREM2 in Alzheimer’s disease: From mechanisms to therapies[J]. Mol Neurodegener, 2025, 20( 1): 43. DOI: 10.1186/s13024-025-00834-z.
    [3]
    ZHANG LH, LIU ST, ZHAO Q, et al. Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease[J]. World J Hepatol, 2025, 17( 2): 102328. DOI: 10.4254/wjh.v17.i2.102328.
    [4]
    SUN HF, FENG JG, TANG LL. Function of TREM1 and TREM2 in liver-related diseases[J]. Cells, 2020, 9( 12): 2626. DOI: 10.3390/cells9122626.
    [5]
    MA K, GUO SL, LI J, et al. Biological and clinical role of TREM2 in liver diseases[J]. Hepatol Commun, 2024, 8( 12): e0578. DOI: 10.1097/hc9.0000000000000578.
    [6]
    HENDRIKX T, PORSCH F, KISS MG, et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH[J]. J Hepatol, 2022, 77( 5): 1373- 1385. DOI: 10.1016/j.jhep.2022.06.004.
    [7]
    MA YN, HU XQ, KARAKO K, et al. The potential and challenges of TREM2-targeted therapy in Alzheimer’s disease: Insights from the INVOKE-2 study[J]. Front Aging Neurosci, 2025, 17: 1576020. DOI: 10.3389/fnagi.2025.1576020.
    [8]
    MEDD M. TREM2 in regulating macrophage inflammatory responses and disease pathogenesis[J]. Crit Rev Immunol, 2025, 45( 2): 15- 24. DOI: 10.1615/critrevimmunol.2024054889.
    [9]
    LIN M, YU JX, ZHANG WX, et al. Roles of TREM2 in the pathological mechanism and the therapeutic strategies of Alzheimer’s disease[J]. J Prev Alzheimers Dis, 2024, 11( 6): 1682- 1695. DOI: 10.14283/jpad.2024.164.
    [10]
    XING JJ, TITUS AR, HUMPHREY MB. The TREM2-DAP12 signaling pathway in Nasu-Hakola disease: A molecular genetics perspective[J]. Res Rep Biochem, 2015, 5: 89- 100. DOI: 10.2147/RRBC.S58057.
    [11]
    WANG XC, QIU ZY, ZHONG ZY, et al. TREM2-expressing macrophages in liver diseases[J]. Trends Endocrinol Metab, 2025: S1043-S2760(25)00084- 0. DOI: 10.1016/j.tem.2025.04.009.
    [12]
    SANTOL J, RAJCIC D, ORTMAYR G, et al. Soluble TREM2 reflects liver fibrosis status and predicts postoperative liver dysfunction after liver surgery[J]. JHEP Rep, 2025, 7( 4): 101226. DOI: 10.1016/j.jhepr.2024.101226.
    [13]
    CHAN MM, HE L, FINCK BN, et al. Cutting edge: Hepatic stellate cells drive the phenotype of monocyte-derived macrophages to regulate liver fibrosis in metabolic dysfunction-associated steatohepatitis[J]. J Immunol, 2024, 213( 3): 251- 256. DOI: 10.4049/jimmunol.2300847.
    [14]
    LI RY, QIN Q, YANG HC, et al. TREM2 in the pathogenesis of AD: A lipid metabolism regulator and potential metabolic therapeutic target[J]. Mol Neurodegener, 2022, 17( 1): 40. DOI: 10.1186/s13024-022-00542-y.
    [15]
    TELEMACO CONTRERAS COLMENARES M, de OLIVEIRA MATOS A, HENRIQUE DOS SANTOS DANTAS P, et al. Unveiling the impact of TREM-2+ Macrophages in metabolic disorders[J]. Cell Immunol, 2024, 405-406: 104882. DOI: 10.1016/j.cellimm.2024.104882.
    [16]
    JI PX, CHEN YX, NI XX, et al. Effect of triggering receptor expressed on myeloid cells 2-associated alterations on lipid metabolism in macrophages in the development of non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2024, 39( 2): 369- 380. DOI: 10.1111/jgh.16417.
    [17]
    WANG XC, HE QF, ZHOU CL, et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development[J]. Immunity, 2023, 56( 1): 58- 77.e11. DOI: 10.1016/j.immuni.2022.11.013.
    [18]
    CAO CH, LIU WW, GUO X, et al. Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning[J]. Front Immunol, 2024, 15: 1460431. DOI: 10.3389/fimmu.2024.1460431.
    [19]
    HAN S, LI XD, XIA N, et al. Myeloid Trem2 dynamically regulates the induction and resolution of hepatic ischemia-reperfusion injury inflammation[J]. Int J Mol Sci, 2023, 24( 7): 6348. DOI: 10.3390/ijms24076348.
    [20]
    XU RN, VUJIĆ N, BIANCO V, et al. Lipid-associated macrophages between aggravation and alleviation of metabolic diseases[J]. Trends Endocrinol Metab, 2024, 35( 11): 981- 995. DOI: 10.1016/j.tem.2024.04.009.
    [21]
    YU WJ, ZHANG Y, SUN LF, et al. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution[J]. Metabolism, 2024, 155: 155911. DOI: 10.1016/j.metabol.2024.155911.
    [22]
    WANG YP, LIN Y, WANG LH, et al. TREM2 ameliorates neuroinflammatory response and cognitive impairment via PI3K/AKT/FoxO3a signaling pathway in Alzheimer's disease mice[J]. Aging, 2020, 12( 20): 20862- 20879. DOI: 10.18632/aging.104104.
    [23]
    FANG C, ZHONG R, LU S, et al. TREM2 promotes macrophage polarization from M1 to M2 and suppresses osteoarthritis through the NF-κB/CXCL3 axis[J]. Int J Biol Sci, 2024, 20( 6): 1992- 2007. DOI: 10.7150/ijbs.91519.
    [24]
    ZHOU C, LIANG CL, ZHANG RR, et al. TREM2 improves coagulopathy and lung inflammation in sepsis through the AKT-mTOR pathway[J]. Int Immunopharmacol, 2025, 150: 114330. DOI: 10.1016/j.intimp.2025.114330.
    [25]
    SHAN SL, CHAO SH, LIU ZD, et al. TREM2 protects against inflammation by regulating the release of mito-DAMPs from hepatocytes during liver fibrosis[J]. Free Radic Biol Med, 2024, 220: 154- 165. DOI: 10.1016/j.freeradbiomed.2024.05.004.
    [26]
    HEEREN J, SCHEJA L. Metabolic-associated fatty liver disease and lipoprotein metabolism[J]. Mol Metab, 2021, 50: 101238. DOI: 10.1016/j.molmet.2021.101238.
    [27]
    SHI SY, ZHOU YY, ZHANG HM, et al. TREM2 in MASH: Integrating lipid metabolism and immune response[J]. Front Immunol, 2025, 16: 1604837. DOI: 10.3389/fimmu.2025.1604837.
    [28]
    HOU JC, ZHANG J, CUI P, et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis[J]. J Clin Invest, 2021, 131( 4): e135197. DOI: 10.1172/JCI135197.
    [29]
    ZHOU LK, QIU XX, MENG ZY, et al. Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation[J]. Sci Transl Med, 2024, 16( 738): eadk1866. DOI: 10.1126/scitranslmed.adk1866.
    [30]
    TANAKA A. Current understanding of primary biliary cholangitis[J]. Clin Mol Hepatol, 2021, 27( 1): 1- 21. DOI: 10.3350/cmh.2020.0028.
    [31]
    YANG YS, HE XS, ROJAS M, et al. Mechanism-based target therapy in primary biliary cholangitis: Opportunities before liver cirrhosis[J]. Front Immunol, 2023, 14: 1184252. DOI: 10.3389/fimmu.2023.1184252.
    [32]
    SARCOGNATO S, SACCHI D, GRILLO F, et al. Autoimmune biliary diseases: Primary biliary cholangitis and primary sclerosing cholangitis[J]. Pathologica, 2021, 113( 3): 170- 184. DOI: 10.32074/1591-951X-245.
    [33]
    LABIANO I, AGIRRE-LIZASO A, OLAIZOLA P, et al. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation[J]. J Hepatol, 2022, 77( 4): 991- 1004. DOI: 10.1016/j.jhep.2022.05.044.
    [34]
    AFONSO MB, RODRIGUES PM, SIMÃO AL, et al. Activation of necroptosis in human and experimental cholestasis[J]. Cell Death Dis, 2016, 7( 9): e2390. DOI: 10.1038/cddis.2016.280.
    [35]
    LUEDDE T, KAPLOWITZ N, SCHWABE RF. Cell death and cell death responses in liver disease: Mechanisms and clinical relevance[J]. Gastroenterology, 2014, 147( 4): 765- 783.e4. DOI: 10.1053/j.gastro.2014.07.018.
    [36]
    PERUGORRIA MJ, ESPARZA-BAQUER A, OAKLEY F, et al. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage[J]. Gut, 2019, 68( 3): 533- 546. DOI: 10.1136/gutjnl-2017-314107.
    [37]
    DE PONTI FF, BUJKO A, LIU ZZ, et al. Spatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair[J]. Immunity, 2025, 58( 2): 362- 380.e10. DOI: 10.1016/j.immuni.2025.01.002.
    [38]
    GUO HR, WANG ML, NI CY, et al. TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2025, 44( 1): 20. DOI: 10.1186/s13046-025-03287-w.
    [39]
    LEI X, GOU YN, HAO JY, et al. Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression[J]. Front Oncol, 2024, 14: 1375729. DOI: 10.3389/fonc.2024.1375729.
    [40]
    ESPARZA-BAQUER A, LABIANO I, SHARIF O, et al. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms[J]. Gut, 2021, 70( 7): 1345- 1361. DOI: 10.1136/gutjnl-2019-319227.
    [41]
    WANG QY, ZHENG K, TAN D, et al. TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2022, 636( Pt 1): 140- 146. DOI: 10.1016/j.bbrc.2022.10.079.
    [42]
    TAN JZ, FAN WZ, LIU T, et al. TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma[J]. J Hepatol, 2023, 79( 1): 126- 140. DOI: 10.1016/j.jhep.2023.02.032.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (24) PDF downloads(8) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return